Evidence map›Paper›PMID 18086705›Full record

ArticleNucleic acids research2008

Human Pcf11 enhances degradation of RNA polymerase II-associated nascent RNA and transcriptional termination.

Steven West, Nicholas J Proudfoot

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Premature transcription termination complex proteins PCF11 and WDR82 silence HIV-1 expression in latently infected cells.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Requirement for cleavage factor IIRNA (New York, N.Y.) · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Life and Death of mRNA Molecules inFrontiers in cellular and infection microbiology · 2018
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Steven WestSir William Dunn School of Pathology, South Parks Road, Oxford, OX1 3RE, UK.
Nicholas J Proudfoot

Funding

Medical Research Council G9826944Wellcome Trust
6 · The paper itself

Abstract

The poly(A) (pA) signal possesses a dual function in 3' end processing of pre-mRNA and in transcriptional termination of RNA polymerase II (Pol II) for most eukaryotic protein-coding genes. A key protein factor in yeast and Drosophila Pol II transcriptional termination is the 3'-end processing factor, Pcf11. In vitro studies suggest that Pcf11 is capable of promoting the dissociation of Pol II elongation complexes from DNA. Moreover, several mutant alleles of yeast Pcf11 effect termination in vivo. However, functions of human Pcf11 (hPcf11) in Pol II termination have not been explored. Here we show that depletion of hPcf11 from HeLa cells reduces termination efficiency. Furthermore, we provide evidence that hPcf11 is required for the efficient degradation of the 3' product of pA site cleavage. Finally, we show that these functions of hPcf11 require an intact pA signal.

Indexed as

RNA 3' End ProcessingRNA StabilityTranscription, GeneticHeLa CellsHumansmRNA Cleavage and Polyadenylation FactorsPoly ARegulatory Sequences, Ribonucleic AcidRNA InterferenceRNA, MessengerRNA Polymerase IIRNA PrecursorsmRNA Cleavage and Polyadenylation FactorsPcf11 protein, humanPoly ARegulatory Sequences, Ribonucleic AcidRNA, MessengerRNA Polymerase IIRNA Precursors

Identifiers

PMID18086705
PMCPMC2241900
OpenAlexW2135800525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.